HDAC 1 inhibitor. Antitumor compound. Antiproliferative. TGF-beta type II receptor inducer. Apoptosis inducer. Anti-inflammatory. Angiogenesis inhibitor. Review.
Storage and Stability:
Short-term Storage: +4°C
Long-term Storage: -20°C
Stable for at least 2 years after receipt when stored at -20°C.
Purity: >98% (NMR)
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference: |
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors: A. Saito, et al.; PNAS 96, 4592 (1999)
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells: B.I. Lee, et al.; Cancer Res. 61, 931 (2001)
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors: J. Jaboin, et al.; Cancer Res. 62, 6108 (2002)
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1: R.R. Rosato, et al.; Cancer Res. 63, 3637 (2003)
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis: Z.Y. Zhang, et al.; Neuroscience 169, 370 (2010)
S-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo: R.K. Srivastava, et al.; Mol. Cancer Ther. 9, 3254 (2010)
MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent: H. Hess-Stumpp, et al.; Int. J. Biochem. Cell Biol. 39, 1388 (2007)
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|